Created at	Source	Raw Value	Validated value
Feb. 2, 2022, 1 p.m.	usa	Frequency and severity of any Adverse Events (AE) up to Day 43 post-vaccination;Immune response as determined by the geometric mean titer (GMT) of SARS-CoV-2-specific neutralizing antibodies;Immune response as determined by the seroconversion rate (SCR) of SARS-CoV-2-specific neutralizing antibodies	Frequency and severity of any Adverse Events (AE) up to Day 43 post-vaccination;Immune response as determined by the geometric mean titer (GMT) of SARS-CoV-2-specific neutralizing antibodies;Immune response as determined by the seroconversion rate (SCR) of SARS-CoV-2-specific neutralizing antibodies
July 14, 2021, 6 a.m.	usa	Frequency and severity of solicited AES (local and systemic reactions) after each and any vaccination;Immune response as determined by the geometric mean titer (GMT) of SARS-CoV-2-specific neutralizing antibodies	Frequency and severity of solicited AES (local and systemic reactions) after each and any vaccination;Immune response as determined by the geometric mean titer (GMT) of SARS-CoV-2-specific neutralizing antibodies